I-Mab Subsidiary Visara Assigns VIS-101 License to Everest Medicines
I-Mab's subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines. This agreement allows Everest Medicines to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries. The information was originally published by I-Mab via EDGAR on October 30, 2025.
I-Mab affiliate NovaBridge’s subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacturing, and commercialization in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-256922), on October 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
